RBRudi Busse

Rudi Busse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rudi Busse has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EDHE: Update on a alternative vasodilator with potential renal significance

    by I. Fleming, R. Busse

    I Fleming, R Busse; EDHE: update on an alternative vasodilator with potential renal significance., Nephrology Dialysis Transplantation, Volume 13, Issue 11, 1


    • 12 April 1996
      • Vol. 157  (1)

    Paracrine functions of the coronary vascular endothelium.

    by I Fleming, J Bauersachs, R Busse


    • 1 March 1994
      • Vol. 44, 392-6

    Control of nitric oxide and prostacyclin synthesis in endothelial cells.

    by R Busse, M Hecker, I Fleming

    Endothelial cells produce a variety of factors involved in the control of vascular tone, platelet activation and cell growth, the most important being nitric oxide (NO) and prostacyclin (PGI2). Although continuously produced in small amounts, synthesis and release of these autacoids are enhanced by mechanical (e.g. fluid shear stress) and humoral stimuli (e.g. acetylcholine, bradykinin, histamine). By counteracting neuro- and myogenic vasoconstriction, the continuous release of NO and PGI2 from the vascular endothelium represents a sensitive and highly effective local system for the maintenance of an adequate blood flow to the organs. This overview resumes current knowledge concerning the intracellular pathways which link endothelial cell activation by receptor-dependent and -independent stimuli to the formation of NO and PGI2.


    • 1 November 1993
      • p. 2-9

    Signal transduction in endothelium-dependent vasodilatation.

    by R Busse, I Fleming, M Hecker

    Modulation of vascular tone is one important function of the endothelium. This can occur via two principal mechanisms: by modulating the local concentration of circulating vasoactive substances (e.g. adenine nucleotides, angiotensin II, biogenic amines, bradykinin), and by synthesizing and releasing vasoactive autacoids. The most important endothelium-derived vasodilator autacoids are nitric oxide (NO) and prostacyclin (PGI2). By counteracting neuro- and myogenic vasoconstriction, the continuous release of these autacoids from the vascular endothelium represents a sensitive and highly effective local system for maintaining an adequate blood flow to the organs. Impaired production of NO (and PGI2), either as a result of endothelial injury or dysfunction, has been implicated in the pathology of a variety of cardiovascular diseases, such as hypertension, hypercholesterolaemia, atherosclerosis and diabetes. Therefore, the prevention and/or reversal of the functional and morphological changes of the endothelium associated with these diseases is an important therapeutic goal. This brief overview covers current knowledge concerning the intracellular pathways that link endothelial activation by receptor-dependent and -independent stimuli to the formation of NO and PGI2.


    • 1 January 1993
      • p. S31-6

    Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy.

    by R Busse, I Fleming, M Hecker

    The effects of angiotensin-converting enzyme (ACE) inhibitors on endothelial autacoid formation were determined in human cultured endothelial cells and in endothelium-intact bovine coronary arteries under resting conditions and after stimulation with bradykinin. Incubation of cultured human endothelial cells with moexiprilat or ramiprilat (0.3 microM) caused a maintained increase in resting intracellular calcium [Ca2+]i, which was prevented by the selective B2-receptor antagonist Hoe 140 (0.1 microM). Both ACE inhibitors also significantly enhanced the increase in [Ca2+]i elicited by bradykinin (3 nM). In parallel with their effect on resting [Ca2+]i, moexiprilat and ramiprilat both induced an increase in intracellular cyclic GMP (cGMP). This increase was prevented by Hoe 140 (0.1 microM) and was abolished by NG-nitro-L-arginine (30 microM), indicating a kinin-induced nitric oxide (NO) formation in this response. The elevation in [Ca2+]i also led to an enhanced production of prostacyclin (PGI2), as indicated by an increase in the concentration of 6-keto prostaglandin F1 alpha (PGF1 alpha) in the cell supernatant. Similar effects of the ACE inhibitors on endothelial autacoid production were observed in endothelium-intact bovine coronary arteries. Like bradykinin (30 nM), moexiprilat (0.3 microM) elicited a nearly twofold increase in the cGMP content of these arteries, which was abolished by both NG-nitro-L-arginine and removal of the endothelium. The functional consequences of this ACE inhibitor-induced increase in vascular cGMP were reflected by a distinct relaxation of arteries preconstricted with PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)